相关实验视频

Updated: May 28, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

改善双重耐火性CLL患者的治疗选择

Ryan Jacobs¹, William Wierda²

¹Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC 28204, USA.

|February 13, 2025

概括

新的治疗方法为慢性淋巴细胞白血病 (CLL) 患者提供了希望,这些患者对共价布鲁顿氨酸激酶抑制剂 (cBTKis) 和venetoclax不耐药. 研究探讨了双重耐火性CLL/SLL的新疗法和抵抗机制.

科学领域:

血液学血液学血液学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

慢性淋巴细胞白血病 (CLL) 和小淋巴细胞淋巴瘤 (SLL) 的细胞生长取决于B细胞受体 (BCR) 信号传递和亡抵抗力.
协同布鲁顿的氨酸激酶抑制剂 (cBTKis) 和venetoclax (BCL2抑制剂) 已经改变了CLL/SLL治疗,超过了化疗免疫疗法.
顺序cBTKi和venetoclax治疗是标准的,但不是治愈的,因此在双重耐药患者中需要治疗.

研究的目的:

审查双重耐火性CLL/SLL患者的治疗选择,这些患者在cBTKis和venetoclax上进展.
在CLL/SLL中讨论新兴疗法和抵抗机制.
突出个性化治疗方法的潜力.

主要方法:

文献综述侧重于双重耐火性CLL/SLL的治疗.
一个双重耐火性CLL患者的案例研究作为讨论的基础.
对包括非共价BTK抑制剂 (ncBTKis),CAR T细胞疗法,双特异性抗体和BTK降解剂在内的新药的分析.

主要成果:

最近批准的皮尔托布鲁丁尼 (ncBTKi) 和利索卡巴丁基马拉利乌塞尔 (CAR T细胞) 显示在双重耐火性CLL/SLL中有效.
几种新型疗法正在临床开发中,为未来的治疗提供了途径.
了解耐药机制是优化治疗策略的关键.

结论:

由于最近的批准,双重耐火性CLL/SLL的有效治疗选择得到了改进.
对新型药物和抗药机制的持续研究有望进一步取得进展.
个性化医疗方法对于管理复杂的CLL/SLL病例至关重要.

关键词:

这是一种B细胞淋巴瘤-2抑制剂.布鲁顿的铁氨基激酶.仿制性抗原受体T细胞疗法慢性淋巴细胞白血病慢性淋巴细胞白血病双重耐火式双重耐火式小型淋巴细胞淋巴瘤.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.